MERCK CMV MK-8228 LET (Kidney Transplant) - Clinical Trial
What is the Purpose of this Study?
If you choose to join this study, you will:
- Be randomized (like flipping a coin) to Group 1 or Group 2
-- Group 1 will get the study drug, Letermovir (LET)
-- Group 2 will get the standard of care medicine, Valganciclovir (VGCV)
- Both groups will also be asked to give blood
Who Can Participate in the Study?
- Have had or will have a kidney transplant within 7 days of signing up for the study
What is Involved?
We are doing this study to learn more about the study drug (Letermovir) and how it can help keep people from getting Human Cytomegalovirus (CMV) disease.